Date: August 6, 2026

Board Meeting Outcomes

  • The Board of Directors meeting was held on August 6, 2026, commencing at 11:30 am and concluding at 1:30 pm.
  • The Board approved and took on record the Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2026.
  • The Board approved and took on record the Limited Review Report by the Auditors on the Unaudited Financial Results for the 1st quarter ended June 30, 2026.

Financial Results (Standalone)

Quarterly Performance (Rs. in lacs)

Income Statement:

  • Revenue from Operations: ₹698.35 (Q1 FY2027) vs ₹548.09 (Q1 FY2026) vs ₹680.91 (Q4 FY2026)
  • Other Income: ₹15.65 (Q1 FY2027) vs ₹1.17 (Q1 FY2026) vs ₹200.36 (Q4 FY2026)
  • Total Income: ₹714.00 (Q1 FY2027) vs ₹549.26 (Q1 FY2026) vs ₹881.27 (Q4 FY2026)

Expense Breakdown:

  • Cost of Material Consumed: (₹0.03) [negative value]
  • Purchase of Stock-in-Trade: ₹50.69
  • Changes in Inventories: (₹9.54) [negative value]
  • Employee Benefits Expenses: ₹277.92
  • Finance Costs: ₹188.05
  • Depreciation and Amortization Expense: ₹158.78
  • Other Expenses: ₹296.61
  • Total Expenses: ₹962.48

Profitability:

  • Profit/(Loss) before exceptional items and tax: (₹248.48) loss
  • Exceptional Items: None
  • Profit/(Loss) before tax: (₹248.48) loss
  • Tax Expense: None
  • Profit/(Loss) for the period: (₹248.48) loss
  • Other Comprehensive Income: None
  • Total Comprehensive Income for the period: (₹248.48) loss

Capital Structure & Metrics:

  • Paid-up Equity Share Capital (Face Value ₹10/- each): ₹2,156.06 lacs
  • Earning Per Share (not Annualized):
  • Basic: (₹1.15)
  • Diluted: (₹1.15)

Annual Comparison (Year Ended March 31, 2026)

  • Revenue from Operations: ₹2,373.16
  • Other Income: ₹202.63
  • Total Income: ₹2,575.79
  • Total Expenses: ₹4,269.10
  • Profit/(Loss) before tax: (₹1,693.31)
  • Profit/(Loss) for the year: (₹1,693.31)
  • Other Comprehensive Income: ₹41.72
  • Total Comprehensive Income: (₹1,651.59)
  • Other Equity: (₹19,536.61)
  • Net Worth: (₹16,275.47)
  • Earning Per Share:
  • Basic: (₹7.85)
  • Diluted: (₹7.85)

Other Operational / Strategic Disclosures

Manufacturing Unit Status:

  • The company's Vizag manufacturing unit has remained closed since February 7, 2025, pursuant to an order from the Andhra Pradesh Pollution Control Board
  • The company has taken various steps and is in constant dialogue with the Pollution Control Board for revocation of the closure order

Amalgamation Plan:

  • The Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited at their meeting held on June 26, 2026
  • The amalgamation is subject to necessary consents/approvals
  • The appointed date for this scheme of amalgamation is April 1, 2026

Segment Information:

  • The company operates in one segment only, hence no segment results have been disclosed

Subsidiary Information:

  • As at June 30, 2026, the company does not have any Subsidiary/Associate/Joint venture companies

Notes to Financial Results

  • The results were reviewed by the Audit Committee and approved by the Board of Directors on August 6, 2026
  • The financial results are prepared in accordance with Indian Accounting Standards (IND AS)
  • Figures of the previous period have been regrouped to conform to the current period's classification wherever necessary
  • The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures for the full financial year 2025-26 and the published year-to-date reviewed figures up to December 31, 2025